IMVT · Immunovant, Inc.
$28.41
-2.37% last session
End-of-day data · close of 2026-10-23
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-10.3
Dividend yield
0.0%
Beta
0.84
Avg volume
1M
Employees
0K
Daily Change %
-2.37%
5 Days Change
8.87%
10 Days Change
1.36%
30 Days Change
-15.75%
60 Days Change
-32.83%
Month to Day Change
-13.52%
Year to Day Change
14.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMVT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-04
Latest call per bank · past 12 months
JP Morgan
Overweight$50.00
+76.0% vs priceCitigroup
Buy$61.00
+114.7% vs priceBank of America
Buy$43.00
+51.4% vs priceGoldman Sachs
Neutral$32.00
+12.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | JP Morgan | Maintains | Overweight | $47.00 → $50.00 |
| 2026-06-30 | Citigroup | Maintains | Buy | $57.00 → $61.00 |
| 2026-05-26 | Guggenheim | Maintains | Buy | $44.00 → $62.00 |
| 2026-05-22 | Truist Securities | Maintains | Hold | $23.00 → $30.00 |
| 2026-05-21 | Bank of America | Maintains | Buy | $32.00 → $43.00 |
| 2026-05-21 | HC Wainwright & Co. | Maintains | Buy | $35.00 → $40.00 |
| 2026-04-15 | Goldman Sachs | Maintains | Neutral | $29.00 → $32.00 |
| 2026-02-10 | HC Wainwright & Co. | Reiterates | Buy | $35.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 32 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 21.2% below the 50-day MA ($36.04).
- bearish: Price vs 200-day MA: Trading 11.1% below the 200-day MA ($31.97).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.15) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($18.74) and high ($44.96).
IMVT Price Chart
Loading chart for IMVT…
Fundamentals
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.